<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Other Uses of RU-486</title>
    <meta content="L17DRU$02" name="slug"/>
    <meta content="17" name="publication_day_of_month"/>
    <meta content="6" name="publication_month"/>
    <meta content="2000" name="publication_year"/>
    <meta content="Saturday" name="publication_day_of_week"/>
    <meta content="Editorial Desk" name="dsk"/>
    <meta content="14" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Opinion" name="online_sections"/>
    <docdata>
      <doc-id id-string="1207902"/>
      <doc.copyright holder="The New York Times" year="2000"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Abortion</classifier>
        <classifier class="indexing_service" type="descriptor">Women</classifier>
        <classifier class="indexing_service" type="descriptor">Ru-486 (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Fibroids</classifier>
        <classifier class="indexing_service" type="descriptor">Tumors</classifier>
        <classifier class="indexing_service" type="descriptor">Gynecology</classifier>
        <org class="indexing_service">Food and Drug Administration</org>
        <person class="indexing_service">Cornell, Drucilla (Prof)</person>
        <classifier class="online_producer" type="types_of_material">Letter</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion/Letters</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/Opinion/Opinion</classifier>
        <classifier class="online_producer" type="general_descriptor">Tumors</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Abortion</classifier>
        <classifier class="online_producer" type="general_descriptor">Women</classifier>
        <classifier class="online_producer" type="general_descriptor">Diseases and Conditions</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20000617T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9C0CE7DF1631F934A25755C0A9669C8B63" item-length="165" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Other Uses of RU-486</hl1>
      </hedline>
      <abstract>
        <p>Prof Drucilla Cornell letter says that unreasonable restrictions proposed by FDA on use of RU-486 abortion drug will deny millions of women only safe non-surgical treatment for fibroid tumors (S)</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>To the Editor:</p>
        <p>I fully agree with your June 10 editorial ''Access to RU-486.'' The unreasonable restrictions proposed by the Food and Drug Administration will not only unfairly limit the drug's availability to poor women seeking safe early abortions, but will also deny millions of other women a proven treatment for fibroid tumors. These tumors, even when noncancerous, can still cause severe problems, including hemorrhaging, kidney damage and infertility, and are the main cause of hysterectomy in the United States.</p>
      </block>
      <block class="full_text">
        <p>To the Editor:</p>
        <p>I fully agree with your June 10 editorial ''Access to RU-486.'' The unreasonable restrictions proposed by the Food and Drug Administration will not only unfairly limit the drug's availability to poor women seeking safe early abortions, but will also deny millions of other women a proven treatment for fibroid tumors. These tumors, even when noncancerous, can still cause severe problems, including hemorrhaging, kidney damage and infertility, and are the main cause of hysterectomy in the United States.</p>
        <p>RU-486 has been found by a number of studies to be the only safe non-surgical treatment for uterine fibroids. For the sake of the millions of women like me who suffer from uterine fibroids, we must demand the immediate release of this drug without unreasonable restrictions.</p>
        <p>DRUCILLA CORNELL  New Brunswick, N.J., June 11, 2000</p>
        <p>The writer is a professor of political science at Rutgers University.</p>
      </block>
    </body.content>
  </body>
</nitf>
